Deadline
Passed
Lead Plaintiff Deadline: September 28, 2021
Please Upload related files below
Fill in below.
Looking for more?
06
Aug 2020
19
Jul 2021
the likelihood that tenapanor would be approved by the Food and Drug Administration (“FDA”). Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug’s treatment effect, making it foreseeably likely that the FDA would not approve the drug.
In order to be included in the lawsuit, you must have incurred a loss on shares of Ardelyx, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Ardelyx, if applicable.
If you suffered a loss in Ardelyx during the relevant time frame, or pursuant to Ardelyx’s IPO if listed above, you have until September 28, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.